Market
Impact of Ro's partnership with Eli Lilly on customer base by mid-2025?
2
Resolution / Starting Odds
Increase by less than 10% • 25%
Increase by 10% to 20% • 25%
Increase by 20% to 30% • 25%
Increase by more than 30% • 25%
Ro's customer base reports and press releases
Story
Ro Partners with Eli Lilly to Offer Lower-Priced Zepbound Vials with Cash-Pay Option
Dec 11, 2024, 01:42 PM
Telehealth company Ro has partnered with pharmaceutical giant Eli Lilly to expand access to Zepbound, a weight-loss drug containing tirzepatide. The partnership will enable Ro to offer lower-priced, single-dose vials of Zepbound through LillyDirect, Eli Lilly's self-pay pharmacy channel. Ro patients with on-label prescriptions will have access to the drug starting Wednesday, with a cash-pay option available. This collaboration comes amid ongoing shortages of semaglutide-based drugs, such as Ozempic, and questions about the future of compounded GLP-1 treatments. The announcement has impacted the stock performance of Hims & Hers Health, Inc. (HIMS), a company that sells compounded semaglutide, with shares falling 3.8% pre-market.
View original story
Similar markets
3-4 new partnerships • 25%
0 new partnerships • 25%
1-2 new partnerships • 25%
5 or more new partnerships • 25%
Decrease • 25%
Significantly increase • 25%
Slightly increase • 25%
No change • 25%
Stock price increases by more than 15% • 25%
Stock price increases by 10% to 15% • 25%
Stock price increases by 5% to 10% • 25%
Stock price increases by less than 5% • 25%
$1 billion to $2 billion • 25%
Less than $1 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Eli Lilly > 60% • 25%
Novo Nordisk 40-60% • 25%
Novo Nordisk > 60% • 25%
Eli Lilly 40-60% • 25%
Neutral • 25%
Highly positive • 25%
Negative • 25%
Somewhat positive • 25%
No significant change • 25%
Increase by 1-5% • 25%
Increase by more than 5% • 25%
Decrease • 25%
No • 50%
Yes • 50%
